AU2025279628A1 — Methods for the administration of certain VMAT2 inhibitors to patients with severe renal impairment
Assigned to Neurocrine Biosciences Inc · Expires 2026-01-15 · 0y expired
What this patent protects
54 Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment. 54 20 25 27 96 28 09 D ec 2 02 5 2 0 2 5 2 7 9 6 2 8 0 9 D e c 2 0 2 5
USPTO Abstract
54 Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment. 54 20 25 27 96 28 09 D ec 2 02 5 2 0 2 5 2 7 9 6 2 8 0 9 D e c 2 0 2 5
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.